Alogliptin is a potent and highly selective inhibitor of DPP-4, >10,000-fold more selective for DPP-4 than other related enzymes including DPP-8 and DPP-9. Alogliptin improves glycaemic control via a glucose-dependent mechanism, whereby insulin release is enhanced and glucagon levels are suppressed when glucose levels are high.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Alogliptin is the active ingredient of these drugs:
Australia Brazil Canada Hong Kong Singapore
Austria Estonia Finland Ireland Lithuania
Alogliptin is also found within below combination drugs:
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):